Life Sciences Archives - Page 3 of 21 - Becker's Hospital Review

Pancreatic cancer pill shows promise | 130+ groups warn on CDC vaccine changes | FDA approves 1st 2-drug HIV treatment | AI life sciences research model debuts | CEOs push back on lawmakers on hospital profits

Cancer drug progress, CDC vaccine concerns, HIV approval and a new AI model. April 29, 2026 1. Pancreatic cancer pill, vaccine show promise: What to know Full story 2. FDA approves 1st 2-drug HIV treatment Full story 3. Healthcare's technology…

Xanax recalled over quality issue | 4 things to know on ibogaine | FDA seeks safety data on new Eli Lilly GLP-1 | 6 new drugs in shortage | 5 FDA moves shaping drug development

FDA oversight updates, new GLP-1 studies and a drugmaker recall. April 22, 2026 1. Drugmaker recalls Xanax over quality issue Full story 2. FDA seeks additional safety data for Lilly GLP-1 pill Full story 3. AI governance, RCM, interoperability —…

Genes may predict GLP-1 success | FDA OKs 1st Farxiga generics | GLP-1s shift care patterns: 4 notes | FDA adds seizure warning to flu vaccine label | Hemophilia gene therapy access halted

New GLP-1 trends, FDA approvals and emerging safety concerns. April 15, 2026 1. Genes may predict GLP-1 weight loss: Study Full story 2. FDA approves 1st generics of Farxiga for Type 2 diabetes Full story 3. Advocate Health, Mayo Clinic…

FDA seeks sweeping budget changes | 200+ active drug shortages persist | Eli Lilly's GLP-1 pill wins FDA nod | COVID study halted | 3.1M eye drops recalled

FDA budget overhaul, 200+ drug shortages and new GLP-1 updates. April 8, 2026 1. FDA seeks sweeping policy changes in budget proposal Full story 2. 216 active drug shortages: How 1 health system is managing Full story 3. Reviewer badge…

Amgen drug faces FDA scrutiny after 8 deaths | FDA OKs 1st weekly basal insulin | Drug supplies at risk amid Iran war | FTC, CVS near antitrust settlement | 13 potential GLP-1 benefits

FDA actions, drug risks and GLP-1 upside: 6 Life Sciences updates April 1, 2026 1. Amgen drug under FDA review in wake of 8 deaths Full story 2. The medications most at risk amid Iran war-driven supply threats Full story…

Stopping GLP-1s tied to 22% rise in heart attacks | Pfizer's Lyme vaccine heads to FDA | Eli Lilly's new GLP-1 cuts weight, A1C | Novel hemophilia gene therapy debuts in Detroit | FDA recalls 89K ibuprofen bottles

GLP-1 risks, a Lyme vaccine, gene therapy debut and an ibuprofen recall in focus. March 25, 2026 1. Stopping GLP-1s linked to 22% rise in heart attack: 5 study notes Full story 2. Pfizer Lyme vaccine candidate heads to FDA…

HHS eyes $200M cancer vaccine push | Senate probes FDA drug denials | Novo missed adverse event reports | Demand grows for unproven autism drug | 3 GLP-1 updates

HHS eyes $200M cancer vaccine effort as FDA faces Senate probe. March 18, 2026 1. HHS plans $200M cancer vaccine initiative: Wall Street Journal Full story 2. Clinicians divided amid growing demand for unproven autism drug Full story 3. Reviewer…

Cancer drug pulled from US market | GLP-1s linked to lower addiction risk | FDA, states review plans to import drugs | Novo, Hims strike GLP-1 deal after legal feud | PE invests $1 trillion in healthcare in a decade

A new GLP-1 study, a cancer drug pulled from the US market and Novo strikes a deal with Hims. March 11, 2026 1. Cancer drug pulled from US market Full story 2. GLP-1 drugs tied to lower addiction risk: Study…

Cancer drug trial paused after death | Novo Nordisk inks $2B obesity drug deal | GLP-1s tied to higher osteoporosis risk | Intellia trial hold lifted | 12 drugs in shortage

Trial pause after patient death, a $2B obesity drug deal and new GLP-1 safety concerns. March 4, 2026 1. Novo Nordisk inks $2.1B oral obesity drug deal Full story 2. FDA partially pauses cancer drug trial after patient death Full…

Bayer sues J&J over cancer drug claims | Zepbound tops Novo Nordisk's GLP-1 in trial | FDA to drop 2-study rule | Schizophrenia, bipolar pill wins FDA OK | 6 healthcare notes from Trump's State of the Union

Drugmaker legal clash, GLP-1 data and FDA policy change. February 25, 2026 1. Bayer sues J&J over prostate cancer drug claims Full story 2. Trump's State of the Union: 6 healthcare takeaways Full story 3. 3,500 healthcare executives. 795 speakers.…